FOREVERGONE IS PROVEN TO REMOVE AND COMPLETELY DESTROY PFAS IN INDUSTRIAL AND MUNICIPAL APPLICATIONS.

^{Gradiant's ForeverGone all-in-one solution and testing data for industrial wastewater (Photo: Business Wire)}



Gradiant announces unique in-house testing capabilities demonstrating PFAS removal to levels below US EPA and European regulatory limits.


BOSTON, Oct 9 (Bernama-BUSINESS WIRE) -- Gradiant, a global solutions provider for advanced water and wastewater treatment, announced today a major milestone in the fight against PFAS contamination, a forever chemical. Working with contaminated industrial, municipal, and landfill waters, ForeverGone^TM has been quantifiably proven, through multiple third-party accredited laboratories, to reduce PFAS to levels below regulatory limits and destroy the resulting PFAS concentrate completely.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241008540101/en/

 

This milestone in development confirms ForeverGone, introduced earlier this year, as the only all-in-one solution capable of removing and destroying PFAS on-site, eliminating the need for waste handling, landfilling, or incineration, differentiating it from conventional technologies, including granular activated carbon (GAC) and ion exchange.

The containerized ForeverGone solution is deployed quickly and commissioned on-site to effectively reduce PFAS to levels below the U.S. EPA's new maximum contaminant level of 4.0 ppt, and the strict limits set by European and Australian regulations.

“Key decision makers appreciate ForeverGone's differentiated proposition to remove and destroy PFAS from all types of contaminated waters,” said Sankar Natarajan, Global Head of Sales at Gradiant. "We're experiencing an unprecedented sales velocity from first engagement to full-scale project deployment across multiple industrial sectors, including semiconductors, food & beverage, mining, and major municipal utilities, all striving to meet regulatory requirements and safeguard their communities."

"To support the development of ForeverGone, we have made a significant investment in the Gradiant Labs' capability to detect PFAS down to just one part per trillion, which uniquely enables us to rapidly offer customer partners the proof they seek of the effectiveness of our technology on their contaminated water," said Steven Lam, Head of Technology at Gradiant.

Gradiant is actively deploying the ForeverGone solution at customer partner sites worldwide, offering them the significant advantage of all-in-one PFAS removal and destruction. Forever.

Are you interested in ForeverGone for your site? Gradiant has introduced a free testing program to demonstrate ForeverGone's ability to treat a wide range of contaminated waters. Interested parties should contact Gradiant at http://www.gradiant.com/contact.

About Gradiant

Gradiant is a Different Kind of Water Company. With a full suite of differentiated and proprietary end-to-end solutions for advanced water and wastewater treatment powered by the top minds in water, the company serves its clients' mission-critical operations in the world's essential industries, including semiconductors, pharmaceuticals, food & beverage, lithium and critical minerals, and renewable energy. Gradiant's innovative solutions reduce water used and wastewater discharged, reclaim valuable resources, and renew wastewater into freshwater. The Boston-headquartered company was founded at MIT and has over 1,000 employees worldwide. Learn more at gradiant.com.

View source version on businesswire.com: 
https://www.businesswire.com/news/home/20241008540101/en/

Contact

Corporate
Felix Wang
Gradiant, Global Head of Brand and PR
fwang@gradiant.com

Source : Gradiant

DUCK CREEK PAYMENTS FACILITATOR PROVIDES SEAMLESS END-TO-END INSURANCE PAYMENT SOLUTION

KUALA LUMPUR, Oct 3 (Bernama) -- Duck Creek Technologies, the intelligent solutions provider defining the future of property and casualty (P&C) and general insurance, introduced its latest insurance-focused payments solution, the Duck Creek Payments Facilitator.

According to Duck Creek Technologies in a statement, this modern, end-to-end payment solution caters to the nuances of payments within insurance by providing carriers with access to digital payment methods for both collecting and disbursing funds.

Its Chief Executive Officer, Michael Jackowski said the Duck Creek Payments Facilitator is designed specifically to address the unique operational demands of insurance carriers.

“By embedding this capability into our broader platform, we are offering carriers a holistic approach that supports flexibility, boosts efficiency, and helps our clients deliver a frictionless experience for policyholders, agents, and vendors,” he said.

Meanwhile, its Chief Product and Technology Officer, Jess Keeney said: “In today’s fast-evolving insurance landscape, carriers require more than just transactional solutions. They need a secure, agile, and future-proof approach to global payment processing.

“The Duck Creek Payments Facilitator delivers exactly that, enabling insurers to effortlessly manage instant claims payouts to real-time premium payments, all from a single, proven solution.”

Duck Creek Payments Facilitator delivers a global solution, combining real-time capabilities, like FedNow, with traditional payments services and Banking as a Service (BaaS) functionalities, such as transactions via push-to-card or digital wallets.

Now insurers can collect or pay out to policyholders using any payment technologies in their market of choice.

Duck Creek Payments includes Duck Creek Payments Facilitator and Duck Creek Payments Orchestrator, introduced earlier this year.

-- BERNAMA

CURIUM JOIN FORCES WITH PEPTIDREAM FOR PROSTATE CANCER THERANOSTICS IN JAPAN

KUALA LUMPUR, Oct 2 (Bernama) -- Curium, a world leader in nuclear medicine, has entered into a strategic partnership with PDRadiopharma Inc, a wholly-owned subsidiary of PeptiDream, for the clinical development, regulatory filing, and commercialisation in Japan of two agents, 177Lu-PSMA-I&T and 64Cu-PSMA-I&T.

Curium will continue to lead global development of the two agents and support PDRadiopharma through technology transfer to support the set-up of manufacturing lines in Japan, including a high throughput Copper 64 manufacturing line based on Curium’s proprietary technology.

According to a statement, Curium and PDRadiopharma have a long-standing relationship in the radiopharmaceutical field.

“As a global innovator in the field of radiopharmaceuticals with a promising late-stage oncology pipeline, Curium is delighted to partner with PDRadiopharma, which has more than four decades of experience in Japan.

“Curium and PDRadiopharma plan to leverage their complementary strengths to accelerate the development of innovative products for the benefit of prostate cancer patients in Japan,” said Curium Chief Executive Officer, International Markets, Chaitanya Tatineni.

The two agents target prostate specific membrane antigen (PSMA) expressed on prostate cancer cells and are being investigated for prostate cancer treatment and diagnostics.

Both target tumours with high levels of PSMA expression, thus potentially forming a theranostic (therapeutic & diagnostic) pair.

PSMA-targeted PET/CT imaging is increasingly emerging as a highly sensitive method for detection of locally recurrent or metastatic lesions in the context of biochemical recurrence and for localisation of primary prostate cancer.

Prostate cancer continues to be widely prevalent in Japan. Annually, there are approximately 90,000 to 100,000 new cases, with patients with metastatic castration-resistant prostate cancer having an overall survival rate of approximately three years in clinical trial settings and even shorter in the real world, and there remains a significant unmet medical need for therapies.

-- BERNAMA